Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477925 | 1.00 | NR3C1 (0.41) | NR3C1PTAFRALDH1A1PDE4APDE4B | |
| SCHEMBL21767999 | 0.75 | PDE4B (0.42) | NR3C1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL21767998 | 0.75 | PDE4B (0.42) | NR3C1ALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL28348174 | 0.73 | PDE4B (0.47) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21768003 | 0.73 | PDE4B (0.47) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21768005 | 0.73 | PDE4B (0.47) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16982124 | 0.71 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL21780878 | 0.71 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL31238162 | 0.71 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL28238744 | 0.70 | CYP1A1 (0.43) | NR3C1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389411-B2 | Pharmaceutical composition, containing NM23 activator, for inhibiting cancer metastasis | EWHA University—Industry Collaboration Foundation (KR) | 2022-07-19 | — | — | US | disclosed |
| US-20200078319-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2020-03-12 | — | — | US | disclosed |
| EP-3616692-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | Ewha University-Industry Collaboration Foundation (KR) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616692-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | Ewha University-Industry Collaboration Foundation (KR) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078319-A1 | PHARMACEUTICAL COMPOSITION, CONTAINING NM23 ACTIVATOR, FOR INHIBITING CANCER METASTASIS | NME1, NTPCR, NME2 | NR3C1 1219/4885PTAFR 787/4885ALDH1A1 4153/4885 |
| US-11389411-B2 | Pharmaceutical composition, containing NM23 activator, for inhibiting cancer metastasis | NME1, NTPCR, NME2 | NR3C1 1219/4885PTAFR 787/4885ALDH1A1 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.